Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Total Enrollment
300 participants
Study Classification
OBSERVATIONAL
Study Start Date
2006-01-01
Study Completion Date
2022-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In this translational research study, Formalin-Fixed-Paraffin-Embedded (FFPE) tumor tissue blocks from patients with early-stage (II-III) colorectal cancer will be assessed for a comprehensive cancer gene panel from NIPD Genetics (https://www.nipd.com/) targeting regions in 37 clinically relevant cancer genes.
The colorectal cancer panel includes an extended list of clinically relevant genes, designed to target clinically actionable and clinically significant mutations that will provide physicians with genetic information regarding a) prediction of the patient's response to targeted therapy, b) prognosis, that is, prediction of clinical outcome, c) diagnosis and molecular classification of colorectal cancer.
The colorectal cancer panel includes an extended list of clinically relevant genes, designed to target clinically actionable and clinically significant mutations that will provide physicians with genetic information regarding a) prediction of the patient's response to targeted therapy, b) prognosis, that is, prediction of clinical outcome, c) diagnosis and molecular classification of colorectal cancer.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Plasma-based Colorectal Cancer Screening Research & Development
NCT04027790
Colo-rectal Cancer
COMPLETED
Blood and Stool Sample Collection in Subjects With a Diagnosis of Colorectal Cancer or Colorectal Lesion: Act Fast
NCT03789162
Colorectal Cancer
COMPLETED
Detection of Colorectal Cancer in Peripheral Blood by Septin 9 DNA Methylation Assay
NCT00696345
Colorectal Cancer
COMPLETED
Prevention and Early Detection Biomarkers of Adenomas and CRC Lesions During CRC Screening
NCT02596113
Colorectal Cancer
COMPLETED
Evaluation of Some Risk Factors Associated With Colorectal Cancer
NCT05170360
Colorectal Neoplasms
UNKNOWN
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Colorectal Cancer
Colon Cancer
Colon Adenocarcinoma
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Gene panel
comprehensive cancer gene panel targeting regions in 37 clinically relevant cancer genes in FFPE tumor tissue blocks
Intervention Type
DIAGNOSTIC_TEST
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Surgically resected early-stage (II-III) colorectal cancer
* Availability of biological material
* Availability of biological material
Exclusion Criteria
* Metastatic disease (stage IV) at initial diagnosis
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hellenic Cooperative Oncology Group
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
George Fountzilas, Prof
Role: STUDY_CHAIR
Hellenic Cooperative Oncology Group
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hellenic Cooperative Oncology Group
Athens, , Greece
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Greece
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet. 2019 Oct 19;394(10207):1467-1480. doi: 10.1016/S0140-6736(19)32319-0.
Reference Type
BACKGROUND
Seufferlein T, Simoes C, Kude F, Ettrich TJ. Molecular Approaches to Metastatic Colorectal Cancer: Better Diagnosis - Better Treatment? Visc Med. 2019 Aug;35(4):259-264. doi: 10.1159/000500617. Epub 2019 Jul 11.
Reference Type
BACKGROUND
Khan K, Valeri N, Dearman C, Rao S, Watkins D, Starling N, Chau I, Cunningham D. Targeting EGFR pathway in metastatic colorectal cancer- tumour heterogeniety and convergent evolution. Crit Rev Oncol Hematol. 2019 Nov;143:153-163. doi: 10.1016/j.critrevonc.2019.09.001. Epub 2019 Sep 7.
Reference Type
BACKGROUND
Cohen R, Rousseau B, Vidal J, Colle R, Diaz LA Jr, Andre T. Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond. Target Oncol. 2020 Feb;15(1):11-24. doi: 10.1007/s11523-019-00690-0.
Reference Type
BACKGROUND
Caputo F, Santini C, Bardasi C, Cerma K, Casadei-Gardini A, Spallanzani A, Andrikou K, Cascinu S, Gelsomino F. BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights. Int J Mol Sci. 2019 Oct 28;20(21):5369. doi: 10.3390/ijms20215369.
Reference Type
BACKGROUND
Oh HH, Joo YE. Novel biomarkers for the diagnosis and prognosis of colorectal cancer. Intest Res. 2020 Apr;18(2):168-183. doi: 10.5217/ir.2019.00080. Epub 2019 Nov 30.
Reference Type
BACKGROUND
De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010 Aug;11(8):753-62. doi: 10.1016/S1470-2045(10)70130-3. Epub 2010 Jul 8.
Reference Type
BACKGROUND
Strimpakos A, Pentheroudakis G, Kotoula V, De Roock W, Kouvatseas G, Papakostas P, Makatsoris T, Papamichael D, Andreadou A, Sgouros J, Zizi-Sermpetzoglou A, Kominea A, Televantou D, Razis E, Galani E, Pectasides D, Tejpar S, Syrigos K, Fountzilas G. The prognostic role of ephrin A2 and endothelial growth factor receptor pathway mediators in patients with advanced colorectal cancer treated with cetuximab. Clin Colorectal Cancer. 2013 Dec;12(4):267-274.e2. doi: 10.1016/j.clcc.2013.07.001. Epub 2013 Sep 17.
Reference Type
BACKGROUND
Pentheroudakis G, Kotoula V, De Roock W, Kouvatseas G, Papakostas P, Makatsoris T, Papamichael D, Xanthakis I, Sgouros J, Televantou D, Kafiri G, Tsamandas AC, Razis E, Galani E, Bafaloukos D, Efstratiou I, Bompolaki I, Pectasides D, Pavlidis N, Tejpar S, Fountzilas G. Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes. BMC Cancer. 2013 Feb 2;13:49. doi: 10.1186/1471-2407-13-49.
Reference Type
BACKGROUND
Pagani F, Randon G, Guarini V, Raimondi A, Prisciandaro M, Lobefaro R, Di Bartolomeo M, Sozzi G, de Braud F, Gasparini P, Pietrantonio F. The Landscape of Actionable Gene Fusions in Colorectal Cancer. Int J Mol Sci. 2019 Oct 25;20(21):5319. doi: 10.3390/ijms20215319.
Reference Type
BACKGROUND
Itatani Y, Kawada K, Yamamoto T, Sakai Y. Resistance to Anti-Angiogenic Therapy in Cancer-Alterations to Anti-VEGF Pathway. Int J Mol Sci. 2018 Apr 18;19(4):1232. doi: 10.3390/ijms19041232.
Reference Type
BACKGROUND
Pentheroudakis G, Mavroeidis L, Papadopoulou K, Koliou GA, Bamia C, Chatzopoulos K, Samantas E, Mauri D, Efstratiou I, Pectasides D, Makatsoris T, Bafaloukos D, Papakostas P, Papatsibas G, Bombolaki I, Chrisafi S, Kourea HP, Petraki K, Kafiri G, Fountzilas G, Kotoula V. Angiogenic and Antiangiogenic VEGFA Splice Variants in Colorectal Cancer: Prospective Retrospective Cohort Study in Patients Treated With Irinotecan-Based Chemotherapy and Bevacizumab. Clin Colorectal Cancer. 2019 Dec;18(4):e370-e384. doi: 10.1016/j.clcc.2019.07.007. Epub 2019 Jul 15.
Reference Type
BACKGROUND
Pentheroudakis G, Kotoula V, Fountzilas E, Kouvatseas G, Basdanis G, Xanthakis I, Makatsoris T, Charalambous E, Papamichael D, Samantas E, Papakostas P, Bafaloukos D, Razis E, Christodoulou C, Varthalitis I, Pavlidis N, Fountzilas G. A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the Hellenic Cooperative Oncology Group (HeCOG). BMC Cancer. 2014 Feb 20;14:111. doi: 10.1186/1471-2407-14-111.
Reference Type
BACKGROUND
Koutras AK, Antonacopoulou AG, Eleftheraki AG, Dimitrakopoulos FI, Koumarianou A, Varthalitis I, Fostira F, Sgouros J, Briasoulis E, Bournakis E, Bafaloukos D, Bompolaki I, Galani E, Kalogeras KT, Pectasides D, Fountzilas G, Kalofonos HP. Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab. Pharmacogenomics J. 2012 Dec;12(6):468-75. doi: 10.1038/tpj.2011.37. Epub 2011 Aug 16.
Reference Type
BACKGROUND
Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009 Apr 9;458(7239):719-24. doi: 10.1038/nature07943.
Reference Type
BACKGROUND
Chin L, Gray JW. Translating insights from the cancer genome into clinical practice. Nature. 2008 Apr 3;452(7187):553-63. doi: 10.1038/nature06914.
Reference Type
BACKGROUND
Forbes SA, Beare D, Boutselakis H, Bamford S, Bindal N, Tate J, Cole CG, Ward S, Dawson E, Ponting L, Stefancsik R, Harsha B, Kok CY, Jia M, Jubb H, Sondka Z, Thompson S, De T, Campbell PJ. COSMIC: somatic cancer genetics at high-resolution. Nucleic Acids Res. 2017 Jan 4;45(D1):D777-D783. doi: 10.1093/nar/gkw1121. Epub 2016 Nov 28.
Reference Type
BACKGROUND
Cancer Genome Atlas Research Network; Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, Ellrott K, Shmulevich I, Sander C, Stuart JM. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. 2013 Oct;45(10):1113-20. doi: 10.1038/ng.2764.
Reference Type
BACKGROUND
Landrum MJ, Lee JM, Riley GR, Jang W, Rubinstein WS, Church DM, Maglott DR. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res. 2014 Jan;42(Database issue):D980-5. doi: 10.1093/nar/gkt1113. Epub 2013 Nov 14.
Reference Type
BACKGROUND
Jennings LJ, Arcila ME, Corless C, Kamel-Reid S, Lubin IM, Pfeifer J, Temple-Smolkin RL, Voelkerding KV, Nikiforova MN. Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists. J Mol Diagn. 2017 May;19(3):341-365. doi: 10.1016/j.jmoldx.2017.01.011. Epub 2017 Mar 21.
Reference Type
BACKGROUND
Koumbaris G, Kypri E, Tsangaras K, Achilleos A, Mina P, Neofytou M, Velissariou V, Christopoulou G, Kallikas I, Gonzalez-Linan A, Benusiene E, Latos-Bielenska A, Marek P, Santana A, Nagy N, Szell M, Laudanski P, Papageorgiou EA, Ioannides M, Patsalis PC. Cell-Free DNA Analysis of Targeted Genomic Regions in Maternal Plasma for Non-Invasive Prenatal Testing of Trisomy 21, Trisomy 18, Trisomy 13, and Fetal Sex. Clin Chem. 2016 Jun;62(6):848-55. doi: 10.1373/clinchem.2015.252502. Epub 2016 Apr 26.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TR6N/19
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Intraoperative Flow Cytometry In Colorectal Cancer
NCT05261542
COMPLETED
Validation of a Molecular Signature for Early Detection of Colorectal Cancer
NCT06738511
COMPLETED
NA
Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas
NCT00843375
RECRUITING
Screening and Risk Factors of Colon Neoplasia
NCT01647776
COMPLETED
Presence of Circulating Tumor DNA in Colorectal Cancer
NCT01198743
COMPLETED
Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies
NCT01260168
COMPLETED
Genetic and Environmental Risk Assessment for Colorectal Cancer in Healthy Participants
NCT00087360
COMPLETED
NA
Study of Biomarkers in Blood & Tissue Samples From Patients With Colorectal Cancer or Polyps & Patients Without Polyps
NCT00898378
COMPLETED
Tumoral Circulating Cells and Colorectal Cancer Progression
NCT03256084
UNKNOWN
NA
Personalized Medicine in Early Stage Colorectal Cancer: Organ Preservation and Immune Benefit
NCT06251726
NOT_YET_RECRUITING
A Multi-center Trial to Establish a Model for the Early Diagnosis of Colorectal Cancer by the Detection of 5-hydroxymethylcytosine (5-hmC) in Plasma Cell-free DNA
NCT03676075
UNKNOWN
Genetic Study of Young Patients With Colorectal Cancer
NCT00044967
COMPLETED
Predicting Disease Progression and/or Recurrence in Cancer
NCT04776837
COMPLETED
Genetic Study in Patients With Stage II or Stage III Colon Cancer
NCT00003833
COMPLETED
A Comparative Study Between Early Onset Colorectal Cancer and Late Onset Colorectal Cancer Patients
NCT06326879
RECRUITING
Treatment Response Prediction System of mCRC Patients Based on CTC
NCT04917276
NOT_YET_RECRUITING
Gene Expression Profiling in Normal Tissue and Tumor Tissue From Patients With Colon Cancer That Has Spread to the Liver, Lungs, or Peritoneum
NCT00896753
COMPLETED
GI SPORE Colon Biosample Protocol
NCT02243267
COMPLETED
Observational Cross-reactivity Study for Colorectal Cancer Diagnosis
NCT06889844
RECRUITING
The Molecular Predisposition to Hereditary Nonpolyposis Colon Cancer (HNPCC)
NCT01447199
UNKNOWN
New bioMarkers tO straTIfy cOlorectal caNcer Referrals
NCT07035691
RECRUITING
Screening Tests in Detecting Colorectal Cancer
NCT00025025
COMPLETED
Molecular Markers of Prognosis in Colorectal Cancer Patients
NCT00220142
COMPLETED
Clinical Validation of ColonAiQ (a Blood-based Assay Targeting ctDNA Methylation) for Colorectal Cancer Detection
NCT06347887
COMPLETED
Colonoscopy or Fecal Occult Blood Test in Screening Healthy Participants for Colorectal Cancer
NCT00102011
ACTIVE_NOT_RECRUITING
PHASE3